Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Jab to be given to premature babies in bid to create ‘protective bubble’ - Experts say the drug will give thousands of ...

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...

Meanwhile, 0.1% of infants in the nirsevimab group and 0.5% of infants in the standard care group were hospitalized for very severe RSV-associated lower respiratory tract infection, with an ...

The new injection, Nirsevimab, will be given to high-risk babies, including those born too early to be protected by the RSV ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...